0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Other Articles |

SULFADIAZINE IN TREATMENT OF RELAPSING MALARIAL INFECTIONS DUE TO PLASMODIUM VIVAX

L. T. COGGESHALL, M.D.; WALTER B. MARTIN; ROBLEY D. BATES Jr.
JAMA. 1945;128(1):7-8. doi:10.1001/jama.1945.02860180009002.
Text Size: A A A
Published online

Interest in malaria has been stimulated in the United States by the high incidence of relapsing malaria in troops returning from service in endemic malaria areas. It has been observed in all hospitals receiving these patients that the relapse rate is high, particularly in Plasmodium vivax malaria. The recognized failure of quinine, atabrine and plasmochin in various dosages, singly and in combinations, to affect the relapse rate materially is a matter of concern and serves to emphasize the importance of developing new methods of treatment. For this reason and because the amount of available quinine has been considerably reduced, a search for more satisfactory compounds continues.

In monkeys the virulent Plasmodium knowlesi strain of malaria is highly susceptible to sulfanilamide.1

Reports concerning the effectiveness of related drugs on human strains have appeared in the literature during the past few years.2 While these reports have been somewhat conflicting, the

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();